High-throughput flow cytometry in drug discovery
A new special issue of SLAS Discovery reflects examples of the recent groundswell of creative new applications for high-throughput flow cytometry (HTFC) in drug discovery.
Led by guest editors Mei Ding, Ph.D. (AstraZeneca) and Bruce S. Edwards, Ph.D. (University of New Mexico), this special issue presents a range of research papers, application notes and technical notes that reflect recent advances in HTFC methods design, provide new expert insight and perspectives, and highlight areas for improvement to broaden the range of HTFC applications in drug discovery.
Examples include descriptions of different software and data analysis workflows; the relative merits of different platforms for assessing biological responses of interest; novel HTFC applications for the development of biologic drugs and novel antibodies; target-agnostic or mechanism-informed phenotypic drug discovery; use of HTFC for single cell analysis; engineering autologous patient T cells to express chimeric antigen receptors (CAR-T) for use in adoptive cellular therapy of malignancies; and more.
Flow cytometry has proven to be a powerful technology, enabling multi-parametric analysis of single cells or particles, and widely used in a broad range of clinical and basic research and applications, including quantification of cell surface and intracellular proteins, DNA analysis, cell proliferation, cell viability, cellular granularity, and cell size. HTFC was made possible by the introduction of novel sample handling and analysis technologies.
Explore the August special issue of SLAS Discovery at http://journals.sagepub.com/toc/jbxb/23/7. For more information about SLAS and its journals, visit http://www.slas.org/journals.
A PDF of this article is available to credentialed media outlets upon request. Contact [email protected]
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).